Employment and the associated impact on quality of life in people diagnosed with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2125-2142

  Bouwmans, Clazien ^a   De Sonneville, Caroline ^a   Mulder, Cornelis L ^b,c   Hakkaart van Roijen, Leona ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

Author keywords

Employment; Environment; Health related quality of life; Mental illness; Patient characteristics; Unemployment; Work

Indexed keywords

AGE DISTRIBUTION; ALCOHOL ABUSE; ARTICLE; COGNITIVE DEFECT; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EMPLOYMENT; EMPLOYMENT RATE; ENVIRONMENTAL FACTOR; HOSPITAL PATIENT; HUMAN; NEGATIVE SYNDROME; OCCUPATION AND OCCUPATION RELATED PHENOMENA; ONSET AGE; OUTPATIENT; POSITIVE SYNDROME; QUALITY OF LIFE; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; UNEMPLOYMENT; VOCATION;

EID: 84939815863     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S83546     Document Type: Article

References (69)

1. Boardman, J, Grove, B, Perkins, R, Shepherd, G. Work and employment for people with psychiatric disabilities. Br J Psychiatry. 2003;182:467–468.
2. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10(1):23–41.
3. Marwaha S, Johnson S. Schizophrenia and employment – a review. Soc Psychiatry Psychiatr Epidemiol. 2004;39(5):337–349.
4. Gladis MM, Gosch EA, Dishuk NM, Crits-Christoph P. Quality of life: expanding the scope of clinical significance. J Consult Clin Psychol. 1999;67(3):320–331.
5. Priebe S, Warner R, Hubschmid T, Eckle I. Employment, attitudes toward work, and quality of life among people with schizophrenia in three countries. Schizophr Bull. 1998;24(3):469–477.
6. Sullivan G, Wells KB, Leake B. Clinical factors associated with better quality of life in a seriously mentally ill population. Hosp Community Psychiatry. 1992;43(8):794–798.
7. Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual Life Res. 1993;2(5):327–333.
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
9. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59–65.
10. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17(1):13–35.
11. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–645.
12. van Os J, Kenis G, Rutten BPF. The environment and schizophrenia. Nature. 2010;468(7321):203–212.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
14. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35 Suppl:S93–S100.
15. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict. 2006;15(5):345–355.
16. Carrà G, Johnson S, Bebbington P, et al. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci. 2012;262(7):607–616.
17. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res. 2001;48(1):109–123.
18. Chan S, Yu Iu W. Quality of life of clients with schizophrenia. J Adv Nurs. 2004;45(1):72–83.
19. Abdel-Baki A, Lesage A, Nicole L, Cossette M, Salvat E, Lalonde P. Schizophrenia, an illness with bad outcome: myth or reality? Can J Psychiatry. 2011;56(2):92–101.
20. Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009;12(4):536–543.
21. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580–1588.
22. Barbui C, Kikkert M, Mazzi MA, et al. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42(5):311–317.
23. Bobes, J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280–286.
24. Boyer L, Aghababian V, Richieri R, et al. Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):271–276.
25. Caron J, Mercier C, Diaz P, Martin A. Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Res. 2005;137(3):203–213.
26. Cechnicki A, Angermeyer MC, Bielańska A. Anticipated and experienced stigma among people with schizophrenia: its nature and correlates. Soc Psychiatry Psychiatr Epidemiol. 2011;46(7):643–650.
27. Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr Serv. 2006;57(8):1102–1109.
28. Compton MT, Rudisch BE, Weiss PS, West JC, Kaslow NJ. Predictors of psychiatrist-reported treatment-compliance problems among patients in routine U.S. psychiatric care. Psychiatry Res. 2005;137(1–2):29–36.
29. Cuyún Carter GB, Milton DR, Ascher-Svanum H, Faries DE. Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry. 2011;11:143.
30. Giugiario M, Crivelli B, Mingrone C, et al. Cognitive function and competitive employment in schizophrenia: relative contribution of insight and psychopathology. Soc Psychiatry Psychiatr Epidemiol. 2012;47(4):553–561.
31. Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A. The Australian National Survey of Psychotic Disorders: profile of psychosocial disability and its risk factors. Psychol Med. 2002;32(4):639–647.
32. Hansson L, Svensson B, Björkman T, et al. What works for whom in a computer-mediated communication intervention in community psychiatry? Moderators of outcome in a cluster randomized trial. Acta Psychiatr Scand. 2008;118(5):404–409.
33. Henry LP, Amminger GP, Harris MG, et al. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. J Clin Psychiatry. 2010;71(6):716–728.
34. Hofer A, Bodner T, Kaufmann A, et al. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol Med. 2011;41(10):2131–2139.
35. Holthausen EA, Wiersma D, Cahn W, et al. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007;149(1–3):71–80.
36. Honkonen T, Stengård E, Virtanen M, Salokangas RK. Employment predictors for discharged schizophrenia patients. Soc Psychiatry Psychiatr Epidemiol. 2007;42(5):372–380.
37. Karadayi G, Emiroğlu B, Uçok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Compr Psychiatry. 2011;52(6):701–707.
38. Kulkarni J, de Castella AR, Filia KM, et al. Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: outcomes. Aust N Z J Psychiatry. 2007;41(12):969–979.
39. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2,960 patients with schizophrenia. J Clin Psychiatry. 2006;67(11):1690–1697.
40. Mackell JA, Harrison DJ, McDonnell DD. Relationship between preventative physical health care and mental health in individuals with schizophrenia: a survey of caregivers. Ment Health Serv Res. 2005;7(4):225–228.
41. Marwaha S, Johnson S, Bebbington PE, et al. Predictors of employment status change over 2 years in people with schizophrenia living in Europe. Epidemiol Psichiatr Soc. 2009;18(4):344–351.
42. Marwaha S, Johnson S, Bebbington P, et al. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry. 2007;191:30–37.
43. Mausbach BT, Depp CA, Bowie CR, et al. Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr Res. 2011;132(2–3):165–170.
44. McCreadie RG; Scottish Comorbidity Study Group. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry. 2002;181:321–325.
45. Mechanic D, Blider S, McAlpine DD. Employing persons with serious mental illness. Health Aff (Millwood). 2002;21(5):242–253.
46. Middelboe T, Mackeprang T, Hansson L, et al. The Nordic Study on schizophrenic patients living in the community. Subjective needs and perceived help. Eur Psychiatry. 2001;16(4):207–214.
47. Mueser KT, Salyers MP, Mueser PR. A prospective analysis of work in schizophrenia. Schizophr Bull. 2001;27(2):281–296.
48. Ramsay CE, Stewart T, Compton MT. Unemployment among patients with newly diagnosed first-episode psychosis: prevalence and clinical correlates in a U.S. sample. Soc Psychiatry Psychiatr Epidemiol. 2012;47(5):797–803.
49. Resnick SG, Rosenheck RA, Canive JM, et al. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008;35(2):215–225.
50. Rosen K, Garety P. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull. 2005;31(3):735–750.
51. Slade E, Salkever D. Symptom effects on employment in a structural model of mental illness and treatment: analysis of patients with schizophrenia. J Ment Health Policy Econ. 2001;4(1):25–34.
52. Spellmann I, Riedel M, Schennach R, et al. One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Res. 2012;198(3):378–385.
53. Thornicroft G, Tansella M, Becker T, et al; EPSILON Study Group. The personal impact of schizophrenia in Europe. Schizophr Res. 2004;69(2–3):125–132.
54. Thorup A, Petersen L, Jeppesen P, et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis. 2007;195(5):396–405.
55. Üçok A, Gorwood P, Karadayı G; EGOFORS. Employment and its relationship with functionality and quality of life in patients with schizophrenia: EGOFORS Study. Eur Psychiatry. 2012;27(6):422–425.
56. Usall, J, Araya S, Ochoa S, Busquets E, Gost A, Márquez M; Assessment Research Group in Schizophrenia (NEDES). Gender differences in a sample of schizophrenic outpatients. Compr Psychiatry. 2001;42(4):301–305.
57. Uzun O, Cansever A, Basoğlu C, Ozşahin A. Smoking and substance abuse in outpatients with schizophrenia: a 2-year follow-up study in Turkey. Drug Alcohol Depend. 2003;70(2):187–192.
58. Waghorn G, Chant D, Jaeger J. Employment functioning and disability among community residents with bipolar affective disorder: results from an Australian community survey. Bipolar Disord. 2007;9(1–2): 166–182.
59. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56(3):283–291.
60. Xie H, McHugo GJ, Helmstetter BS, Drake RE. Three-year recovery outcomes for long-term patients with co-occurring schizophrenic and substance use disorders. Schizophr Res. 2005;75(2–3):337–348.
61. Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. Psychiatry Clin Neurosci. 2012;66(4):313–321.
62. Eklund M, Hansson L, Bejerholm U. Relationships between satisfaction with occupational factors and health-related variables in schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol. 2001;36(2):79–83.
63. Marwaha S, Johnson S, Bebbington P, et al; EuroSC Study Group. Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. J Nerv Ment Dis. 2008;196(2):87–94.
64. Palmer BW, Heaton RK, Gladsjo JA, et al. Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophr Res. 2002;55(3):205–215.
65. Rosenheck R, Leslie D, Keefe R, et al; CATIE Study Investigators Group. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163(3):411–417.
66. Kilian R, Becker T. Macro-economic indicators and labour force participation of people with schizophrenia. J Ment Health. 2007;16(2):211–222.
67. van der Wel KA, Dahl E, Thielen K. Social inequalities in ‘sickness’: European welfare states and non-employment among the chronically ill. Soc Sci Med. 2011;73(11):1608–1617.
68. Brekke JS, Levin S, Wolkon GH, Sobel E, Slade E. Psychosocial functioning and subjective experience in schizophrenia. Schizophr Bull. 1993;19(3):599–608.
69. Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health. 2011;14(6):907–920.